282 related articles for article (PubMed ID: 24827739)
1. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.
Jiang H; Clise-Dwyer K; Ruisaard KE; Fan X; Tian W; Gumin J; Lamfers ML; Kleijn A; Lang FF; Yung WK; Vence LM; Gomez-Manzano C; Fueyo J
PLoS One; 2014; 9(5):e97407. PubMed ID: 24827739
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.
Jiang H; Rivera-Molina Y; Gomez-Manzano C; Clise-Dwyer K; Bover L; Vence LM; Yuan Y; Lang FF; Toniatti C; Hossain MB; Fueyo J
Cancer Res; 2017 Jul; 77(14):3894-3907. PubMed ID: 28566332
[TBL] [Abstract][Full Text] [Related]
3. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.
Phillips LM; Li S; Gumin J; Daou M; Ledbetter D; Yang J; Singh S; Parker Kerrigan BC; Hossain A; Yuan Y; Gomez-Manzano C; Fueyo J; Lang FF
Neuro Oncol; 2021 Nov; 23(11):1911-1921. PubMed ID: 34059921
[TBL] [Abstract][Full Text] [Related]
4. Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection.
Grekova SP; Raykov Z; Zawatzky R; Rommelaere J; Koch U
Cancer Gene Ther; 2012 Jul; 19(7):468-75. PubMed ID: 22539062
[TBL] [Abstract][Full Text] [Related]
5. The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.
Kleijn A; Kloezeman J; Treffers-Westerlaken E; Fulci G; Leenstra S; Dirven C; Debets R; Lamfers M
PLoS One; 2014; 9(5):e97495. PubMed ID: 24866126
[TBL] [Abstract][Full Text] [Related]
6. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models.
Martínez-Vélez N; Garcia-Moure M; Marigil M; González-Huarriz M; Puigdelloses M; Gallego Pérez-Larraya J; Zalacaín M; Marrodán L; Varela-Guruceaga M; Laspidea V; Aristu JJ; Ramos LI; Tejada-Solís S; Díez-Valle R; Jones C; Mackay A; Martínez-Climent JA; García-Barchino MJ; Raabe E; Monje M; Becher OJ; Junier MP; El-Habr EA; Chneiweiss H; Aldave G; Jiang H; Fueyo J; Patiño-García A; Gomez-Manzano C; Alonso MM
Nat Commun; 2019 May; 10(1):2235. PubMed ID: 31138805
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.
Tähtinen S; Grönberg-Vähä-Koskela S; Lumen D; Merisalo-Soikkeli M; Siurala M; Airaksinen AJ; Vähä-Koskela M; Hemminki A
Cancer Immunol Res; 2015 Aug; 3(8):915-25. PubMed ID: 25977260
[TBL] [Abstract][Full Text] [Related]
8. Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET.
Garcia-Moure M; Gonzalez-Huarriz M; Labiano S; Guruceaga E; Bandres E; Zalacain M; Marrodan L; de Andrea C; Villalba M; Martinez-Velez N; Laspidea V; Puigdelloses M; Gallego Perez-Larraya J; Iñigo-Marco I; Stripecke R; Chan JA; Raabe EH; Kool M; Gomez-Manzano C; Fueyo J; Patiño-García A; Alonso MM
Clin Cancer Res; 2021 Mar; 27(6):1807-1820. PubMed ID: 33376098
[TBL] [Abstract][Full Text] [Related]
9. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice.
Shin DH; Jiang H; Gillard AG; Kim D; Fan X; Singh SK; Nguyen TT; Sohoni SS; Lopez-Rivas AR; Parthasarathy A; Ene CI; Gumin J; Lang FF; Alonso MM; Gomez-Manzano C; Fueyo J
Mol Ther; 2024 Mar; 32(3):722-733. PubMed ID: 38311852
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity.
Jiang H; Shin DH; Yi Y; Fan X; Gumin J; He J; Gillard AG; Lang FF; Gomez-Manzano C; Fueyo J
Cancer Res Commun; 2023 Jun; 3(6):1118-1131. PubMed ID: 37379361
[TBL] [Abstract][Full Text] [Related]
11. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
12. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
Chen D; Huang L; Zhou H; Zhang Y
Front Immunol; 2021; 12():615089. PubMed ID: 33717103
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site.
Lopes A; Feola S; Ligot S; Fusciello M; Vandermeulen G; Préat V; Cerullo V
J Immunother Cancer; 2019 Jul; 7(1):174. PubMed ID: 31291991
[TBL] [Abstract][Full Text] [Related]
14. Critical Role of Autophagy in the Processing of Adenovirus Capsid-Incorporated Cancer-Specific Antigens.
Klein SR; Jiang H; Hossain MB; Fan X; Gumin J; Dong A; Alonso MM; Gomez-Manzano C; Fueyo J
PLoS One; 2016; 11(4):e0153814. PubMed ID: 27093696
[TBL] [Abstract][Full Text] [Related]
15. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway.
Fueyo J; Alemany R; Gomez-Manzano C; Fuller GN; Khan A; Conrad CA; Liu TJ; Jiang H; Lemoine MG; Suzuki K; Sawaya R; Curiel DT; Yung WK; Lang FF
J Natl Cancer Inst; 2003 May; 95(9):652-60. PubMed ID: 12734316
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma.
de Jonge J; Berghauser Pont LM; Idema S; Kloezeman JJ; Noske D; Dirven CM; Lamfers ML
J Gene Med; 2013; 15(3-4):134-41. PubMed ID: 23606319
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS
Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006
[TBL] [Abstract][Full Text] [Related]
18. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.
Koks CA; Garg AD; Ehrhardt M; Riva M; Vandenberk L; Boon L; De Vleeschouwer S; Agostinis P; Graf N; Van Gool SW
Int J Cancer; 2015 Mar; 136(5):E313-25. PubMed ID: 25208916
[TBL] [Abstract][Full Text] [Related]
19. GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory.
Rivera-Molina Y; Jiang H; Fueyo J; Nguyen T; Shin DH; Youssef G; Fan X; Gumin J; Alonso MM; Phadnis S; Lang FF; Gomez-Manzano C
Neurooncol Adv; 2019; 1(1):vdz009. PubMed ID: 31608328
[TBL] [Abstract][Full Text] [Related]
20. Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas.
Jiang H; Shin DH; Nguyen TT; Fueyo J; Fan X; Henry V; Carrillo CC; Yi Y; Alonso MM; Collier TL; Yuan Y; Lang FF; Gomez-Manzano C
Clin Cancer Res; 2019 Nov; 25(22):6801-6814. PubMed ID: 31455679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
